A detailed history of Norden Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Norden Group LLC holds 16,573 shares of HALO stock, worth $1 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
16,573
Previous 12,816 29.31%
Holding current value
$1 Million
Previous $521 Million 66.44%
% of portfolio
0.18%
Previous 0.11%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$37.81 - $52.4 $142,052 - $196,866
3,757 Added 29.31%
16,573 $868 Million
Q1 2024

Apr 30, 2024

SELL
$33.68 - $41.95 $5.2 Million - $6.48 Million
-154,468 Reduced 92.34%
12,816 $521 Million
Q1 2024

Apr 19, 2024

BUY
$33.68 - $41.95 $5.34 Million - $6.65 Million
158,559 Added 1817.3%
167,284 $6.81 Billion
Q4 2023

Feb 05, 2024

BUY
$33.32 - $42.1 $102,958 - $130,089
3,090 Added 54.84%
8,725 $322 Million
Q3 2023

Nov 06, 2023

BUY
$36.46 - $44.03 $205,452 - $248,109
5,635 New
5,635 $215 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.42B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Norden Group LLC Portfolio

Follow Norden Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norden Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Norden Group LLC with notifications on news.